SMYD2 and triple-negative breast carcinoma: Over the past several decades, extensive research has shed light on the pivotal role of SMYD2 in various cancer types, including lung adenocarcinoma, cervical cancer, triple-negative breast cancer, and pancreatic ductal adenocarcinoma.